Advertisement
Screener

ZYMEWORKS INC. (ZYME) APIC, Share-based Payment Arrangement, Increase for Cost Recognition

1.9 / 5 stars · 23/62 Roast Me

ZYMEWORKS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition

ZYMEWORKS INC. (ZYME) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital

us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06

  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.11M, a 92.44% increase year-over-year.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.88M, a 1.30% increase year-over-year.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $6.38M, a 58.32% increase year-over-year.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.77M, a 17.99% increase year-over-year.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $27.07M, a 61.93% increase from fiscal 2024.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $16.72M, a 103.95% increase from fiscal 2023.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $8.20M, a 13.87% decline from fiscal 2022.
  • ZYMEWORKS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $9.52M, a 75.14% decline from fiscal 2021.
Period endAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 monthAPIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month
2026-06-30$11.11M
10-Q · filed 2026-08-06
$17.99M
derived: sum of 2 quarters · filed 2026-08-06
2026-03-31$6.88M
10-Q · filed 2026-08-06
2025-12-31$27.07M
10-K · filed 2026-03-02
2025-09-30$6.38M
10-Q · filed 2025-11-06
$12.15M
derived: sum of 2 quarters · filed 2026-08-06
$18.94M
derived: sum of 3 quarters · filed 2026-08-06
2025-06-30$5.77M
10-Q · filed 2026-08-06
$12.56M
derived: sum of 2 quarters · filed 2026-08-06
2025-03-31$6.79M
10-Q · filed 2026-08-06
2024-12-31$16.72M
10-K · filed 2026-03-02
2024-09-30$4.03M
10-Q · filed 2025-11-06
$8.92M
derived: sum of 2 quarters · filed 2025-11-06
$12.35M
derived: sum of 3 quarters · filed 2025-11-06
2024-06-30$4.89M
10-Q · filed 2025-11-06
$8.33M
derived: sum of 2 quarters · filed 2025-11-06
2024-03-31$3.44M
10-Q · filed 2025-11-06
2023-12-31$8.20M
10-K · filed 2026-03-02
2023-09-30$2.69M
10-Q · filed 2024-10-31
$3.43M
derived: sum of 2 quarters · filed 2024-10-31
$5.62M
derived: sum of 3 quarters · filed 2024-10-31
2023-06-30$742.00K
10-Q · filed 2024-10-31
$2.94M
derived: sum of 2 quarters · filed 2024-10-31
2023-03-31$2.20M
10-Q · filed 2024-10-31
2022-12-31$9.52M
10-K · filed 2025-03-05
2022-09-30$4.38M
10-Q · filed 2023-11-07
$8.84M
derived: sum of 2 quarters · filed 2023-11-07
$5.90M
derived: sum of 3 quarters · filed 2023-11-07
2022-06-30$4.45M
10-Q · filed 2023-11-07
$1.52M
derived: sum of 2 quarters · filed 2023-11-07
2022-03-31-$2.93M
10-Q · filed 2023-11-07
2021-12-31$38.27M
10-K · filed 2024-03-06
2021-09-30$10.33M
10-Q · filed 2022-11-08
$21.42M
derived: sum of 2 quarters · filed 2022-11-08
$29.95M
derived: sum of 3 quarters · filed 2022-11-08
2021-06-30$11.09M
10-Q · filed 2022-11-08
$19.62M
derived: sum of 2 quarters · filed 2022-11-08
2021-03-31$8.53M
10-Q · filed 2022-11-08
2020-12-31$26.95M
10-K · filed 2023-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Sarepta Therapeutics, Inc. (SRPT)United States$1.941B-13.89
AGIOS PHARMACEUTICALS, INC. (AGIO)United States$1.962B-5.38
Biohaven Ltd. (BHVN)United States$1.990B-3.83
COMPASS Pathways plc (CMPS)$1.812B-4.87
ANI PHARMACEUTICALS INC (ANIP)United States$1.810B18.77
Nuvation Bio Inc. (NUVB)United States$2.007B-13.12
UroGen Pharma Ltd. (URGN)$2.015B-18.42
Septerna, Inc. (SEPN)United States$1.783B-63.01
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05
Xencor Inc (XNCR)United States$1.776B-7.33